Denali Therapeutics Inc.

Rachel Prorok

Mark S Dennis

Ankita Srivastava

Bettina Van Lengerich

Joshua I Park

Kathryn M Monroe

Gunasekaran Kannan

Adam P Silverman

Mihalis S Kariolis

Cathal S Mahon

Katrina W Lexa

Zhenyu Gu

Ju Shi

Riley Walsh

Gerald Maxwell Cherf

Ray L Y Low

Sherie Duncan

Kathleen Lisaingo

In one aspect, antibodies that specifically bind to a human triggering receptor expressed on myeloid cells 2 (TREM2) protein are provided. In some embodiments, the antibody decreases levels of soluble TREM2 (sTREM2). In some embodiments, the antibody enhances TREM2 activity.

Anti-TREM2 antibodies and methods of use thereof

Provided herein are progranulin variants and fusion proteins that comprise a progranulin variant and an Fc polypeptide. Methods of using such proteins to treat progranulin-associated disorders (e.g., a neurodegenerative disease, such as frontotemporal dementia (FTD)) are also provided herein.

Progranulin variants

Growing community of inventors

South San Francisco, CA, United States of America

Rachel Prorok